NCT04141319

Brief Summary

The PAINLESS study is a single-center, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled clinical study to compare the efficacy and safety of pre-emptive scalp infiltration with ropivacaine plus ketorolac and ropivacaine alone for postoperative pain relief in adults undergoing elective supratentorial craniotomies.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_4 pain

Timeline
Completed

Started Dec 2021

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 20, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 28, 2019

Completed
2.1 years until next milestone

Study Start

First participant enrolled

December 1, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

January 22, 2020

Status Verified

January 1, 2020

Enrollment Period

7 months

First QC Date

October 20, 2019

Last Update Submit

January 21, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • cumulative doses of patient-controlled analgesia (PCA) butorphanol consumption from 0 to 48 h postoperatively

    The primary outcome measure will be cumulative doses of PCA butorphanol consumption from 0 to 48 h postoperatively

    0 to 48 hours postoperatively

Secondary Outcomes (14)

  • The time to first request for patient-controlled analgesia butorphanol

    Within 48hours postoperatively

  • frequency of pressing patient-controlled analgesia pump

    Within 48hours postoperatively

  • numeral rating scale (NRS) Score

    at 2 hours, 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 1 month, 3 months and 6 months postoperatively

  • Pain control satisfaction score (PCSS) postoperatively

    at 24 hours, 48 hours, 72 hours, 1 week, 1 month, 3 months and 6 months

  • Ramsay sedation score (RSS)

    at 2 hours, 4 hours, 8 hours, 24 hours and 48 hours and 72 hours postoperatively

  • +9 more secondary outcomes

Study Arms (2)

The ketorolac group

EXPERIMENTAL

Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.

Drug: KetorolacDrug: RopivacaineDrug: Epinephrine

The control group

ACTIVE COMPARATOR

In the control group, preoperative peri-incisional scalp infiltration will be performed using 30ml of 60 mg ropivacaine and 0.1mg epinephrine.

Drug: RopivacaineDrug: Epinephrine

Interventions

30ml of local infiltration solution containing 60mg ropivacaine

The ketorolac group

30ml of local infiltration solution containing 6mg ketorolac

The control groupThe ketorolac group

30ml of local infiltration solution containing 0.1mg epinephrine

The control groupThe ketorolac group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Scheduled for elective supratentorial tumour resection;
  • Planned general anaesthesia;
  • American Society of Anesthesiologists (ASA) physical status I - II;
  • Age ranging from 18 to 65 years old;
  • Participates required to fix their head in a head clamp intraoperatively;
  • Participates with an anticipated awake within 2 hours after surgery.

You may not qualify if:

  • Allergy/intolerance to study drugs including anesthetic drugs, ketorolac and epinephrine;
  • Expected delayed extubation or no plan to extubate;
  • History of neurosurgeries;
  • Long-term use of analgesics and sedatives (more than 2 weeks)
  • Receiving any painkiller within 24 h before the operation;
  • Extreme body mass index (BMI) (less than 15 or more than 35);
  • Patients with impaired cardiopulmonary;
  • Patients with impaired renal function;
  • Patients with impaired hepatic function;
  • History of chronic headache;
  • Patients with cognitive deficit;
  • Patients with intellectual disability;
  • Patients with uncontrolled epilepsy;
  • Patients with psychiatric disorders;
  • Difficulties in using PCA device
  • +6 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Vacas S, Van de Wiele B. Designing a pain management protocol for craniotomy: A narrative review and consideration of promising practices. Surg Neurol Int. 2017 Dec 6;8:291. doi: 10.4103/sni.sni_301_17. eCollection 2017.

    PMID: 29285407BACKGROUND
  • Andersen KV, Nikolajsen L, Haraldsted V, Odgaard A, Soballe K. Local infiltration analgesia for total knee arthroplasty: should ketorolac be added? Br J Anaesth. 2013 Aug;111(2):242-8. doi: 10.1093/bja/aet030. Epub 2013 Mar 20.

    PMID: 23514638BACKGROUND
  • Solovyova O, Lewis CG, Abrams JH, Grady-Benson J, Joyce ME, Schutzer SF, Arumugam S, Caminiti S, Sinha SK. Local infiltration analgesia followed by continuous infusion of local anesthetic solution for total hip arthroplasty: a prospective, randomized, double-blind, placebo-controlled study. J Bone Joint Surg Am. 2013 Nov 6;95(21):1935-41. doi: 10.2106/JBJS.L.00477.

    PMID: 24196463BACKGROUND
  • Song J, Li L, Yu P, Gao T, Liu K. Preemptive scalp infiltration with 0.5% ropivacaine and 1% lidocaine reduces postoperative pain after craniotomy. Acta Neurochir (Wien). 2015 Jun;157(6):993-8. doi: 10.1007/s00701-015-2394-8. Epub 2015 Apr 7.

    PMID: 25845547BACKGROUND

MeSH Terms

Conditions

Pain

Interventions

KetorolacRopivacaineEpinephrine

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

IndomethacinIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesEthanolaminesAmino AlcoholsAlcoholsBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

  • Fang Luo, M.D

    Beijing Tiantan Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Department of Pain Management

Study Record Dates

First Submitted

October 20, 2019

First Posted

October 28, 2019

Study Start

December 1, 2021

Primary Completion

July 1, 2022

Study Completion

December 1, 2022

Last Updated

January 22, 2020

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will share